Wise Equity takes majority stake in E-Pharma Trento

Italian private equity firm Wise Equity completed the majority buyout of E-Pharma Trento S.p.A., a specialized contract development and manufacturing organization (CDMO) focused on oral solid dose forms. The transaction was structured as a corporate carve-out and partial divestiture from Unifarm S.p.A., a regional pharmaceutical cooperative comprising approximately 800 pharmacist-members across northern Italy and Sardinia. Unifarm rolled over a significant minority equity stake into the new holding structure alongside Wise Equity to preserve strategic alignment. The acquisition represents the eighth platform deployment from Wise Equity’s current fund. For FY2025, E-Pharma Trento generated annual revenue of €50–100M. Led by Wise Equity Senior Partner Stefano Ghetti and Unifarm President Paolo Cainelli, the investment thesis focuses on scaling E-Pharma’s proprietary drug-delivery technologies across global pharmaceutical and nutraceutical markets. Proceeds will fund expanded R&D investments in specialized oral formulation platforms (such as effervescent, orally disintegrating, and sublingual dose technologies) and finance a programmatic buy-and-build playbook targeting bolt-on acquisitions of complementary manufacturing technologies and international CDMO capabilities. On the buy-side, Wise Equity was advised by M&A adviser Finerre, with KPMG conducting financial due diligence, Deloitte STP managing tax structuring, Simmons & Simmons acting as legal counsel, and ERM delivering ESG due diligence. On the sell-side, Unifarm and E-Pharma were advised by financial adviser Deutsche Bank, with Valli-Mancuso e Associati serving as legal counsel, and Studio Scozzi Dottori Commercialisti handling accounting and tax advisory.